{
    "id": "67a52e71-74e5-4790-accf-dc9f2f761705",
    "indications": {
        "text": "premarin ( conjugated estrogens ) vaginal cream mixture estrogens indicated : \u2022 treatment atrophic vaginitis kraurosis vulvae ( 1.1 ) \u2022 treatment moderate severe dyspareunia , symptom vulvar vaginal atrophy , due menopause ( 1.2 )",
        "doid_entities": [
            {
                "text": "atrophic vaginitis (DOID:11968)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11968"
            },
            {
                "text": "vaginitis (DOID:2170)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2170"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "generally , estrogen prescribed postmenopausal woman uterus , progestin also considered reduce risk endometrial cancer [ boxed warning ] . woman without uterus need progestin . cases , however , hysterectomized women history endometriosis may need progestin [ ( 5.3 , 5.15 ) ] . estrogen-alone , combination progestin , lowest effective dose shortest duration consistent treatment goals risks individual woman . postmenopausal women re-evaluated periodically clinically appropriate determine treatment still necessary .",
        "doid_entities": [
            {
                "text": "endometrial cancer (DOID:1380)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1380"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "endometriosis (DOID:289)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_289"
            }
        ],
        "orphanet_entities": []
    },
    "adverseReactions": "premarin vaginal cream contraindicated women following conditions : \u2022 undiagnosed abnormal genital bleeding [ ( 5.3 ) ] \u2022 breast cancer history breast cancer [ ( 5.3 ) ] \u2022 estrogen-dependent neoplasia [ ( 5.3 ) ] \u2022 active dvt , pe , history conditions [ ( 5.2 ) ] \u2022 active arterial thromboembolic disease ( example , stroke myocardial infarction ) , history conditions [ ( 5.2 ) ] \u2022 known anaphylactic reaction angioedema premarin [ ( 5.16 , 5.17 ) ] \u2022 hepatic impairment disease [ ( 5.11 ) ] \u2022 protein c , protein antithrombin deficiency known thrombophilic disorders",
    "ingredients": [
        {
            "name": "ESTROGENS, CONJUGATED",
            "code": "IU5QR144QX"
        },
        {
            "name": "CETYL ALCOHOL",
            "code": "936JST6JCN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "WHITE WAX",
            "code": "7G1J5DA97F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_73702"
        },
        {
            "name": "GLYCERYL MONOSTEARATE",
            "code": "230OU9XXE4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11250"
        },
        {
            "name": "PROPYLENE GLYCOL MONOPALMITOSTEARATE",
            "code": "F76354LMGR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "METHYL STEARATE",
            "code": "8D4NXF3ZH7",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_69188"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "MINERAL OIL",
            "code": "T5L8T28FGP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_46662"
        }
    ],
    "organization": "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",
    "name": "Premarin",
    "effectiveTime": "20250502",
    "indications_original": "PREMARIN (conjugated estrogens) vaginal cream is a mixture of estrogens indicated for: \u2022 Treatment of Atrophic Vaginitis and Kraurosis Vulvae ( 1.1 ) \u2022 Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause ( 1.2 )",
    "contraindications_original": "Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer [see Boxed Warning].\n                  \n                  A woman without a uterus does not need a progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin [see Warnings and Precautions (5.3, 5.15)]. \n                  Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.",
    "adverseReactions_original": "PREMARIN vaginal cream is contraindicated in women with any of the following conditions: \n                  \n                     \n                        \u2022\n                        Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.3)]\n                        \n                     \n                     \n                        \u2022\n                        Breast cancer or a history of breast cancer [see Warnings and Precautions (5.3)]\n                        \n                     \n                     \n                        \u2022\n                        Estrogen-dependent neoplasia [see Warnings and Precautions (5.3)]\n                        \n                     \n                     \n                        \u2022\n                        Active DVT, PE, or a history of these conditions [see Warnings and Precautions (5.2)]\n                        \n                     \n                     \n                        \u2022\n                        Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions [see Warnings and Precautions (5.2)]\n                        \n                     \n                     \n                        \u2022\n                        Known anaphylactic reaction or angioedema to PREMARIN [see Warnings and Precautions (5.16,\n                              5.17)]\n                        \n                     \n                     \n                        \u2022\n                        Hepatic impairment or disease [see Warnings and Precautions (5.11)]\n                        \n                     \n                     \n                        \u2022\n                        Protein C, protein S or antithrombin deficiency or other known thrombophilic disorders",
    "drug": [
        {
            "name": "Premarin",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12290"
        }
    ]
}